Ypsilon Therapeutics
Waltham
About Ypsilon Therapeutics
Ypsilon Therapeutics develops T cell receptor mimics(TCRm) against validated tumor antigens.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.7M
- Last round: Grant (Jan 2025)
- Website: https://ypsilontx.com/
Industries & Categories
Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ypsilon-therapeutics-10884 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.